Hope, caution for Washington state patients 'first in line' for new schizophrenia drug

Hope, caution for Washington state patients 'first in line' for new schizophrenia drug

Cobenfy was approved by the Food and Drug Administration in fall 2024 and represents the first novel approach in decades to treating schizophrenia, which affects an estimated 3.7 million American adults. The drug is now beginning to make its way into the hands of Washingtonians.

Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or…

How to Communicate With Someone With Schizophrenia

Learn what to say — and what not to say — to a loved one with schizophrenia to keep the lines of communication open, helpful, and supportive.

“In depression and anxiety, people are already more aware, but in diseases such as schizophrenia, families don't understand”

Luye Pharma Launches ERZOFRI® in U.S. for Schizophrenia Treatment

PRINCETON, N.J., April 7, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy for the treatment of adults with schizoaffective disorder. ERZOFRI, administered once a month, delivers the active ingredient, paliperidone, through a lon…